This Cinqair or Cinqaero market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth during the historic period can be attributed to factors such as the increasing prevalence of eosinophilic asthma, a higher incidence of allergic and inflammatory conditions, growing recognition of the impact of eosinophilic inflammation on asthma control and exacerbations, greater awareness among healthcare providers, and the rise of new biologic treatments.
The expected growth in the forecast period is driven by rising awareness of the disease, increased global healthcare spending, greater awareness of personalized management strategies, changes in lifestyle and dietary patterns, the approval of new and innovative drugs for treatment, favorable reimbursement policies, and growing healthcare expenditures. Key trends in the forecast period include the launch of emerging therapies, the development of novel therapeutics, the integration of digital technologies, ongoing research and development activities, and the availability of alternative therapies.
The growing levels of air pollution are expected to significantly drive the growth of the cinqair (Cinqaero) market. Air pollution refers to the presence of harmful substances such as gases, particles, and biological molecules in the air, which can adversely affect human health and the environment. The main contributors to increasing air pollution include the burning of fossil fuels, industrial emissions, vehicle exhaust, and agricultural activities. Cinqair (Cinqaero) helps counteract the effects of air pollution by improving lung function and reducing inflammation, which can enhance respiratory health and alleviate the pressure on healthcare systems often burdened by environmental pollutants. For example, in 2023, the Environmental Protection Agency (EPA) reported that approximately 66 million tons of pollution were emitted in the United States. As a result, the rising levels of air pollution are fueling the growth of the cinqair (Cinqaero) market.
The increasing demand for biological products is expected to contribute to the growth of the cinqair (Cinqaero) market. Biological products are complex pharmaceutical substances derived from living organisms and are used to diagnose, prevent, treat, and cure various diseases and medical conditions. The demand for biological products is growing due to environmental concerns, heightened consumer awareness, and the need for more sustainable and effective alternatives to synthetic chemicals. Biologics such as Cinqair (Cinqaero) help by targeting immune system components, such as interleukin-5 (IL-5), which plays a key role in eosinophilic asthma. By reducing airway inflammation and improving respiratory function, Cinqair (Cinqaero) benefits asthma patients, especially those whose condition is triggered by environmental factors such as air pollution or allergens. For example, in October 2024, the U.S. Food and Drug Administration (FDA) reported that by the end of 2022, 40 biosimilars had been approved, with 27 available in the U.S. This rising demand for biological products is driving the growth of the cinqair (Cinqaero) market.
The increasing prevalence of asthma is expected to propel the growth of the cinqair (Cinqaero) market. Asthma is caused by a combination of genetic and environmental factors, including family history, allergies, respiratory infections during childhood, air pollution, and exposure to triggers such as pollen, dust mites, and tobacco smoke. Cinqair (Cinqaero) assists asthma patients by targeting and inhibiting interleukin-5 (IL-5), a protein that plays a crucial role in the inflammation process associated with eosinophilic asthma. By reducing airway inflammation, improving lung function, and decreasing asthma exacerbations caused by allergens or environmental factors, Cinqair (Cinqaero) offers significant benefits. For instance, in July 2024, the American Lung Association reported that 44.2 million Americans, or 13.5% of the population, had been diagnosed with asthma by a healthcare professional in 2022. This rising prevalence of asthma is therefore contributing to the growth of the cinqair (Cinqaero) market.
The key company operating in the cinqair or cinqaero market is Teva Pharmaceuticals.
North America was the largest region in the cinqair or cinqaero market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in cinqair or cinqaero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Cinqair (also known as Cinqaero) refers to reslizumab, a humanized monoclonal antibody primarily used to treat severe eosinophilic asthma in adults. It works by targeting and inhibiting interleukin-5 (IL-5), a key regulator of eosinophil production, effectively reducing eosinophil levels and inflammation in the body.
The main clinical indication for cinqair or cinqaero is severe eosinophilic asthma. This subtype of asthma is characterized by high levels of eosinophils, a type of white blood cell that contributes to airway inflammation. The medication is used for children, adults, and teenagers, and is distributed through various end users, including hospitals, clinics, ambulatory care centers, and home care settings.
The cinqair or cinqaero market research report is one of a series of new reports that provides cinqair or cinqaero market statistics, including cinqair or cinqaero industry global market size, regional shares, competitors with a cinqair or cinqaero market share, detailed cinqair or cinqaero market segments, market trends, and opportunities, and any further data you may need to thrive in the cinqair or cinqaero industry. This cinqair or cinqaero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The countries covered in the cinqair or cinqaero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cinqair or cinqaero market consists of sales of reslizumab in forms such as intravenous solutions, single-use vials, and pre-mixed infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth during the historic period can be attributed to factors such as the increasing prevalence of eosinophilic asthma, a higher incidence of allergic and inflammatory conditions, growing recognition of the impact of eosinophilic inflammation on asthma control and exacerbations, greater awareness among healthcare providers, and the rise of new biologic treatments.
The expected growth in the forecast period is driven by rising awareness of the disease, increased global healthcare spending, greater awareness of personalized management strategies, changes in lifestyle and dietary patterns, the approval of new and innovative drugs for treatment, favorable reimbursement policies, and growing healthcare expenditures. Key trends in the forecast period include the launch of emerging therapies, the development of novel therapeutics, the integration of digital technologies, ongoing research and development activities, and the availability of alternative therapies.
The growing levels of air pollution are expected to significantly drive the growth of the cinqair (Cinqaero) market. Air pollution refers to the presence of harmful substances such as gases, particles, and biological molecules in the air, which can adversely affect human health and the environment. The main contributors to increasing air pollution include the burning of fossil fuels, industrial emissions, vehicle exhaust, and agricultural activities. Cinqair (Cinqaero) helps counteract the effects of air pollution by improving lung function and reducing inflammation, which can enhance respiratory health and alleviate the pressure on healthcare systems often burdened by environmental pollutants. For example, in 2023, the Environmental Protection Agency (EPA) reported that approximately 66 million tons of pollution were emitted in the United States. As a result, the rising levels of air pollution are fueling the growth of the cinqair (Cinqaero) market.
The increasing demand for biological products is expected to contribute to the growth of the cinqair (Cinqaero) market. Biological products are complex pharmaceutical substances derived from living organisms and are used to diagnose, prevent, treat, and cure various diseases and medical conditions. The demand for biological products is growing due to environmental concerns, heightened consumer awareness, and the need for more sustainable and effective alternatives to synthetic chemicals. Biologics such as Cinqair (Cinqaero) help by targeting immune system components, such as interleukin-5 (IL-5), which plays a key role in eosinophilic asthma. By reducing airway inflammation and improving respiratory function, Cinqair (Cinqaero) benefits asthma patients, especially those whose condition is triggered by environmental factors such as air pollution or allergens. For example, in October 2024, the U.S. Food and Drug Administration (FDA) reported that by the end of 2022, 40 biosimilars had been approved, with 27 available in the U.S. This rising demand for biological products is driving the growth of the cinqair (Cinqaero) market.
The increasing prevalence of asthma is expected to propel the growth of the cinqair (Cinqaero) market. Asthma is caused by a combination of genetic and environmental factors, including family history, allergies, respiratory infections during childhood, air pollution, and exposure to triggers such as pollen, dust mites, and tobacco smoke. Cinqair (Cinqaero) assists asthma patients by targeting and inhibiting interleukin-5 (IL-5), a protein that plays a crucial role in the inflammation process associated with eosinophilic asthma. By reducing airway inflammation, improving lung function, and decreasing asthma exacerbations caused by allergens or environmental factors, Cinqair (Cinqaero) offers significant benefits. For instance, in July 2024, the American Lung Association reported that 44.2 million Americans, or 13.5% of the population, had been diagnosed with asthma by a healthcare professional in 2022. This rising prevalence of asthma is therefore contributing to the growth of the cinqair (Cinqaero) market.
The key company operating in the cinqair or cinqaero market is Teva Pharmaceuticals.
North America was the largest region in the cinqair or cinqaero market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in cinqair or cinqaero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Cinqair (also known as Cinqaero) refers to reslizumab, a humanized monoclonal antibody primarily used to treat severe eosinophilic asthma in adults. It works by targeting and inhibiting interleukin-5 (IL-5), a key regulator of eosinophil production, effectively reducing eosinophil levels and inflammation in the body.
The main clinical indication for cinqair or cinqaero is severe eosinophilic asthma. This subtype of asthma is characterized by high levels of eosinophils, a type of white blood cell that contributes to airway inflammation. The medication is used for children, adults, and teenagers, and is distributed through various end users, including hospitals, clinics, ambulatory care centers, and home care settings.
The cinqair or cinqaero market research report is one of a series of new reports that provides cinqair or cinqaero market statistics, including cinqair or cinqaero industry global market size, regional shares, competitors with a cinqair or cinqaero market share, detailed cinqair or cinqaero market segments, market trends, and opportunities, and any further data you may need to thrive in the cinqair or cinqaero industry. This cinqair or cinqaero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The countries covered in the cinqair or cinqaero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cinqair or cinqaero market consists of sales of reslizumab in forms such as intravenous solutions, single-use vials, and pre-mixed infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cinqair or Cinqaero Market Characteristics4. Cinqair or Cinqaero Market Trends and Strategies5. Cinqair or Cinqaero Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Cinqair or Cinqaero Pricing Analysis & Forecasts30. Global Cinqair or Cinqaero Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Cinqair or Cinqaero Market32. Recent Developments in the Cinqair or Cinqaero Market
3. Cinqair or Cinqaero Market Biologic Drug Characteristics
6. Global Cinqair or Cinqaero Growth Analysis and Strategic Analysis Framework
8. Cinqair or Cinqaero Market Segmentation
9. Global Cinqair or Cinqaero Epidemiology of Clinical Indications
10. Cinqair or Cinqaero Market Regional and Country Analysis
11. Asia-Pacific Cinqair or Cinqaero Market
12. China Cinqair or Cinqaero Market
13. India Cinqair or Cinqaero Market
14. Japan Cinqair or Cinqaero Market
15. Australia Cinqair or Cinqaero Market
16. South Korea Cinqair or Cinqaero Market
17. Western Europe Cinqair or Cinqaero Market
18. UK Cinqair or Cinqaero Market
19. Germany Cinqair or Cinqaero Market
20. France Cinqair or Cinqaero Market
21. Eastern Europe Cinqair or Cinqaero Market
22. North America Cinqair or Cinqaero Market
23. USA Cinqair or Cinqaero Market
24. Canada Cinqair or Cinqaero Market
25. South America Cinqair or Cinqaero Market
26. Middle East Cinqair or Cinqaero Market
27. Africa Cinqair or Cinqaero Market
28. Cinqair or Cinqaero Market Competitive Landscape and Company Profiles
29. Global Cinqair or Cinqaero Market Pipeline Analysis
33. Cinqair or Cinqaero Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Cinqair or Cinqaero Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cinqair or cinqaero market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cinqair or cinqaero? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cinqair or cinqaero market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Severe Eosinophilic Asthma2) by Application: Children; Adults; Teenagers
3) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Teva Pharmaceuticals
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Teva Pharmaceuticals
